Heterogeneity in Signaling Pathway Activity within Primary and between Primary and Metastatic Breast Cancer

SIMPLE SUMMARY: Personalized breast cancer treatment with targeted therapy (e.g., tamoxifen or PI3K inhibitors) requires identification of responder patients. Phenotypical heterogeneity within the primary, and between primary tumor and metastases, may however interfere with response to therapy, if b...

Descripción completa

Detalles Bibliográficos
Autores principales: Inda, Márcia A., van Swinderen, Paul, van Brussel, Anne, Moelans, Cathy B., Verhaegh, Wim, van Zon, Hans, den Biezen, Eveline, Bikker, Jan Willem, van Diest, Paul J., van de Stolpe, Anja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002348/
https://www.ncbi.nlm.nih.gov/pubmed/33809754
http://dx.doi.org/10.3390/cancers13061345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002348/
https://www.ncbi.nlm.nih.gov/pubmed/33809754
http://dx.doi.org/10.3390/cancers13061345

Ejemplares similares